©NIJRMS
Publications 2024

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

NEWPORT INTERNATIONAL JOURNAL OF RESEARCH IN MEDICAL SCIENCES (NIJRMS)

Volume 5 Issue 3 2024

https://doi.org/10.59298/NIJRMS/2024/5.3.6570

Innovations in HIV Prevention and Treatment: The Future of HIV Care

Mugisha Emmanuel K.

Faculty of Science and Technology Kampala International University Uganda

ABSTRACT

The Human Immunodeficiency Virus (HIV) continues to pose a significant global health challenge, despite substantial progress in treatment and prevention. This review explored recent innovations in HIV prevention and treatment, highlighting advancements such as long-acting pre-exposure prophylaxis (PrEP), long-acting injectable antiretroviral therapy (ART), and emerging research into potential cures. It also examined integrated care approaches, digital health innovations, and innovative financing models that are shaping the future of HIV care. The review synthesized recent research, evaluated the impact of these innovations, and discussed future directions to advance global health goals. The methodology for this review involved a comprehensive analysis of current literature, clinical trial data, and expert opinions to provide a holistic overview of how these advancements are transforming HIV care and addressing existing challenges.

Keywords: HIV Innovations, Prevention Strategies, Long-Acting ART, Integrated Care Models, Digital Health Technologies.

INTRODUCTION

The Human Immunodeficiency Virus (HIV) remains a persistent global health challenge, affecting millions worldwide and contributing to significant morbidity and mortality [1,2]. Despite substantial progress in understanding the virus and developing treatment strategies, the fight against HIV is far from over. Historically, the epidemic has been shaped by numerous scientific and medical advancements, with antiretroviral therapy (ART) transforming HIV from a fatal disease into a manageable chronic condition [3-5]. However, achieving global health goals requires not only continued improvement in treatment but also innovative approaches to prevention and care [6]. Recent years have witnessed remarkable innovations in HIV prevention and treatment, reflecting a dynamic landscape of research and technological advancement. These innovations offer new possibilities for reducing transmission rates, improving patient outcomes, and ultimately moving closer to the goal of ending the HIV epidemic [7,8]. Key developments include novel preventive measures such as long-acting pre-exposure prophylaxis (PrEP), advances in treatment modalities like long-acting injectable ART, and emerging research into potential cures [9]. Additionally, integrated care models, digital health technologies, and innovative financing strategies are shaping the future of HIV care [10,11]. This review explores the cutting-edge innovations that are redefining HIV prevention and treatment. By examining recent advancements, evaluating their impact, and discussing future directions, this review aims to provide a comprehensive overview of how these innovations are poised to transform HIV care. Understanding and leveraging these developments are crucial for overcoming existing challenges, addressing health disparities, and advancing toward a future where HIV is no longer a global health threat.

INNOVATIONS IN HIV PREVENTION

Innovations in HIV prevention have made significant strides in reducing transmission rates and enhancing the efficacy of preventive measures. Key advancements include:

i. Long-Acting Pre-Exposure Prophylaxis (PrEP)

Traditional PrEP, involving daily oral antiretroviral medications, has been a pivotal tool in preventing HIV. Recent innovations include long-acting formulations, such as injectable PrEP, which offer extended protection with fewer doses. These long-acting options improve adherence and convenience, particularly for populations at high risk of HIV [12,13].

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

ii. **HIV Vaccines**

Research into HIV vaccines is progressing to induce strong and lasting immune responses against the virus [14]. Recent clinical trials have focused on candidate vaccines that target different stages of the HIV lifecycle, aiming to provide effective long-term protection. Although a fully effective HIV vaccine is still in development, progress in this area holds promise for future prevention strategies [15,16].

iii. **Microbicides**

Topical microbicides, applied vaginally or rectally, offer a novel approach to preventing HIV transmission. These products contain antiretroviral agents that can reduce the risk of infection upon exposure. Recent innovations include the development of long-acting microbicides with improved efficacy and user-friendliness [18,19].

iv. **Self-Testing and Self-Management**

Advances in self-testing technologies empower individuals to monitor their HIV status and manage their health more proactively [20]. Home-based rapid HIV tests and digital health platforms provide convenient and private options for testing and monitoring, facilitating early detection and reducing barriers to accessing care [21,22].

v. **Enhanced Harm Reduction Strategies**

Innovations in harm reduction, such as needle exchange programs and supervised injection facilities, have proven effective in reducing HIV transmission among people who inject drugs. New approaches include integrating harm reduction with broader healthcare services to address multiple health and social needs [23].

INNOVATIONS IN HIV TREATMENT

Innovations in HIV treatment have significantly improved the management of the virus, leading to better health outcomes and enhanced quality of life for people living with HIV. Key advancements include:

i. **Long-acting antiretroviral Therapy (ART)**

Long-acting formulations of ART, including injectables and implants, offer a major leap forward in treatment convenience. These therapies reduce the frequency of dosing from daily to monthly or even quarterly, which can improve adherence and simplify treatment regimens for patients [24,25].

ii. **Broadly Neutralizing Antibodies (bNAbs)**

bNAbs are a class of antibodies that can target and neutralize a wide range of HIV strains. Recent developments in bNAb therapy show potential for reducing viral loads and enhancing immune responses. Clinical trials are exploring their use as both treatment and preventive measures [26,27].

iii. **Single-Tablet Regimens (STRs)**

STRs combine multiple antiretroviral drugs into a single pill, streamlining treatment and improving adherence. These regimens simplify dosing and minimize the pill burden, making it easier for patients to maintain consistent treatment [28].

iv. **Optimized Drug Formulations**

Advances in drug formulations, including better-tolerated medications with fewer side effects and improved pharmacokinetics, contribute to more effective and patient-friendly treatment options. These formulations address issues such as pill size, taste, and gastrointestinal side effects [29].

v. **Precision Medicine**

Personalized approaches to HIV treatment involve tailoring therapy based on genetic, environmental, and lifestyle factors unique to each patient. Precision medicine aims to optimize treatment efficacy and minimize adverse effects by considering individual variations in drug metabolism and resistance profiles [30,31].

INTEGRATED CARE APPROACHES

Integrated care approaches represent a transformative shift in managing HIV by coordinating HIV services with other essential health services [32]. This holistic model addresses multiple health needs simultaneously, enhancing overall care and improving patient outcomes. Combining HIV care with services for co-infections like tuberculosis (TB) and hepatitis, as well as managing non-communicable diseases (NCDs), ensures that individuals receive coordinated and comprehensive care [33]. This approach minimizes fragmentation, reduces the burden on healthcare systems, and improves health outcomes by addressing the full spectrum of a patient's health needs. Integrating HIV services with maternal and child health programs is crucial for preventing mother-to-child transmission (PMTCT) and supporting the health of HIV-positive pregnant women and their children [34]. This integration ensures that both maternal and child health needs are addressed, providing a continuum of care that extends from prenatal to postnatal periods. By incorporating sexual and reproductive health services into HIV care, providers can address issues such as contraceptive needs, sexual health education, and screening for sexually transmitted infections (STIs). This integration promotes holistic care and supports individuals in managing their sexual and reproductive health alongside HIV treatment. Addressing mental health and substance use disorders in conjunction with HIV care is critical for improving adherence and overall health. Integrated care models that include mental health support and substance use treatment help patients manage the psychological and behavioral aspects of living with HIV, leading to better adherence to treatment and improved outcomes. Integrated care emphasizes patient-centered approaches, where care is tailored to the individual's needs and preferences

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

[26,32,35]. This approach fosters better engagement with healthcare services, reduces barriers to care, and improves patient satisfaction and adherence to treatment regimens.

DIGITAL HEALTH INNOVATIONS

Digital health innovations are revolutionizing HIV care by leveraging technology to enhance prevention, treatment, and support services [36]. mHealth solutions, such as mobile apps and text messaging services, facilitate remote consultations, provide appointment reminders, and offer adherence support. These tools improve access to care, especially in remote or underserved areas, and enhance patient engagement by delivering timely health information and reminders. Telemedicine platforms allow for virtual consultations, remote monitoring, and follow-up, ensuring continuity of care while reducing the burden on healthcare facilities [37,38]. This approach is particularly valuable for individuals who face barriers to in-person visits, such as those in rural areas or with mobility issues. Innovations like electronic pill dispensers and adherence-tracking apps help monitor medication intake and remind patients to take their antiretroviral therapy (ART) as prescribed [39]. These tools can improve adherence rates by providing real-time feedback and support to individuals managing their HIV treatment. Advanced data analytics and AI are used to analyze large datasets, identify patterns, and predict outcomes. These technologies enable personalized treatment plans and early intervention strategies by analyzing patient data, adherence patterns, and treatment responses. Integrated health information systems facilitate the management and sharing of patient data across different healthcare providers [40,41]. These systems enhance coordination of care, streamline patient management, and support better decision-making by providing comprehensive and up-to-date health records.

INNOVATIVE FINANCING MODELS

Innovative financing models are crucial for sustaining and scaling up HIV prevention and treatment programs. These models mobilize additional resources and enhance the effectiveness of HIV interventions through diverse financial strategies:

i. Blended Finance

This model combines public and private investments to fund HIV programs. By leveraging public funds to attract private investment, blended finance increases the overall pool of resources available for HIV initiatives. It helps de-risk investments and incentivizes private sector involvement in addressing global health challenges [42,43].

ii. Public-Private Partnerships (PPPs)

PPPs bring together governments, private companies, and non-governmental organizations to collaborate on HIV care projects. These partnerships pool expertise, resources, and financial support to implement innovative solutions, expand service delivery, and improve access to care [44,45].

iii. Social Impact Bonds (SIBs)

SIBs are performance-based funding mechanisms where private investors provide upfront capital for HIV programs. Returns on investment are contingent upon achieving specific health outcomes, such as improved treatment adherence or reduced transmission rates. This model aligns financial incentives with measurable health results, driving efficiency and accountability [46].

iv. Development Impact Bonds (DIBs)

Similar to SIBs, DIBs focus on achieving development goals by attracting investment for HIV programs. Investors receive returns based on the success of the programs in meeting predefined outcomes, such as increased access to ART or enhanced prevention efforts. DIBs emphasize results-oriented funding and scalable interventions [47].

v. Crowdfunding and Digital Fundraising

Online platforms enable individuals and organizations to raise funds for HIV-related projects through crowdfunding campaigns. These platforms harness the power of digital networks to gather support from a global audience, raising awareness and financial resources for targeted interventions and research [48].

CONCLUSION

The relentless pursuit of solutions to the HIV epidemic has led to remarkable innovations in prevention, treatment, and care, shaping a promising future for HIV management. Recent advancements, including long-acting pre-exposure prophylaxis (PrEP), long-acting injectable antiretroviral therapies, and the exploration of broadly neutralizing antibodies, have significantly enhanced our ability to prevent and treat HIV. Moreover, integrated care approaches have emerged as transformative strategies, ensuring comprehensive and coordinated care that addresses the multifaceted needs of individuals living with HIV. Digital health innovations are further revolutionizing HIV care by improving access, adherence, and personalized treatment through technology-driven solutions. In addition, innovative financing models, such as blended finance, public-private partnerships, and social impact bonds, are crucial for sustaining and expanding HIV programs, ensuring that resources are effectively mobilized and allocated. Together, these innovations represent a multi-faceted approach to combating HIV, emphasizing the need for continued research, collaboration, and investment. The ongoing challenge remains to translate these innovations into widespread, equitable access and to address persistent disparities in HIV care. By leveraging these advancements, we can move closer to achieving global health goals and ultimately end the HIV

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

epidemic. Continued commitment to innovation, integration, and financing will be essential in overcoming the remaining obstacles and achieving a future where HIV is no longer a global health threat.

REFERENCES

1. Lule, F. (2021). Global Burden of HIV/AIDS. In: Kickbusch, I., Ganten, D., Moeti, M. (eds) Handbook of Global Health. Springer, Cham. https://doi.org/10.1007/978-3-030-45009-0_31
2. Aturinde, A., Farnaghi, M., Pilesjö, P. *et al.* Spatial analysis of HIV-TB co-clustering in Uganda. *BMC Infect Dis* **19**, 612 (2019). https://doi.org/10.1186/s12879-019-4246-2
3. Alum EU, Obeagu EI, Ugwu OPC, Egba SI, EjimUti DE, Ukaidi CUA, Echegu DA. Confronting Dual Challenges: Substance Abuse and HIV/AIDS. Elite Journal of HIV, 2024; 2(5): 1-8. https://epjournals.com/journals/EJHIV
4. Colvin, C.J. HIV/AIDS, chronic diseases and globalisation. *Global Health* **7**, 31 (2011). https://doi.org/10.1186/1744-8603-7-31
5. Ayodeji Bayo Ogunrotifa, At the helm of haart: The experience of biographical time among people living with hiv in Nigeria, Social Sciences & Humanities Open, 2021; 3(1): 100135. https://doi.org/10.1016/j.ssaho.2021.100135.
6. Kruk ME, Gage AD, Arsenault C, Jordan K, Leslie HH, Roder-DeWan S et al.,. High-quality health systems in the Sustainable Development Goals era: time for a revolution. Lancet Glob Health. 2018 Nov;6(11):e1196-e1252. doi: 10.1016/S2214-109X(18)30386-3. Epub 2018 Sep 5. PMID: 30196093; PMCID: PMC7734391.
7. Alum, E. U., Obeagu, E. I., Ugwu, O. P.C., Aja, P. M. and Okon, M. B. HIV Infection and Cardiovascular diseases: The obnoxious Duos. *Newport International Journal of Research in Medical Sciences (NIJRMS)*, 2023; 3(2): 95-99. https://nijournals.org/wp-content/uploads/2023/07/NIJRMS-3-295-99-2023.pdf.
8. Valentin Fuster, Jendayi Frazer, Megan Snair, Rajesh Vedanthan, Victor Dzau, Jendayi Frazer, The Future Role of the United States in Global Health: Emphasis on Cardiovascular Disease, Journal of the American College of Cardiology, 2017; 70(25): 3140-3156, https://doi.org/10.1016/j.jacc.2017.11.009.
9. Agrahari V, Anderson SM, Peet MM, Wong AP, Singh ON, Doncel GF, Clark MR. Long-acting HIV pre-exposure prophylaxis (PrEP) approaches: recent advances, emerging technologies, and development challenges. Expert Opin Drug Deliv. 2022 Oct;19(10):1365-1380. doi: 10.1080/17425247.2022.2135699. Epub 2022 Oct 25. PMID: 36252277; PMCID: PMC9639748.
10. Flexner C. The future of long-acting agents for preexposure prophylaxis. Curr Opin HIV AIDS. 2022 Jul 1;17(4):192-198. doi: 10.1097/COH.0000000000000735. PMID: 35762373; PMCID: PMC9467455.
11. Toska, E., Zhou, S., Chen-Charles, J. *et al.* Factors Associated with Preferences for Long-Acting Injectable Antiretroviral Therapy Among Adolescents and Young People Living with HIV in South Africa. *AIDS Behav* **27**, 2163–2175 (2023). https://doi.org/10.1007/s10461-022-03949-2
12. Cobb DA, Smith NA, Edagwa BJ, McMillan JM. Long-acting approaches for delivery of antiretroviral drugs for prevention and treatment of HIV: a review of recent research. Expert Opin Drug Deliv. 2020 Sep;17(9):1227-1238. doi: 10.1080/17425247.2020.1783233. Epub 2020 Jul 6. PMID: 32552187; PMCID: PMC7442675.
13. Alum, E. U.,Ugwu, O. P.C., Obeagu, E. I. and Okon, M. B. Curtailing HIV/AIDS Spread: Impact of Religious Leaders. *Newport International Journal of Research in Medical Sciences (NIJRMS)*, 2023; 3(2): 28-31.https://nijournals.org/wp-content/uploads/2023/06/NIJRMS-32-28-31-2023-rm.pdf
14. Kaur A, Vaccari M. Exploring HIV Vaccine Progress in the Pre-Clinical and Clinical Setting: From History to Future Prospects. Viruses. 2024 Feb 27;16(3):368. doi: 10.3390/v16030368. PMID: 38543734; PMCID: PMC10974975.
15. Ng'uni T, Chasara C, Ndhlovu ZM. Major Scientific Hurdles in HIV Vaccine Development: Historical Perspective and Future Directions. Front Immunol. 2020 Oct 28; 11:590780. doi: 10.3389/fimmu.2020.590780. PMID: 33193428; PMCID: PMC7655734.
16. Obeagu, E.I., Alum, E.U. and Obeagu, G.U. Factors Associated with Prevalence of HIV Among Youths: A Review of Africa Perspective. *Madonna University Journal of Medicine and Health Sciences*, 2023;**3**(1): 13-18. https://madonnauniversity.edu.ng/journals/index.php/medicine
17. Alum, E. U., Ugwu, O. P. C., Obeagu, E. I., Aja, P. M., Okon, M. B., Uti, D. E. Reducing HIV Infection Rate in Women: A Catalyst to reducing HIV Infection pervasiveness in Africa. International Journal of Innovative and Applied Research. 2023; 11(10):01-06. DOI:10.58538/IJIAR/2048. http://dx.doi.org/10.58538/IJIAR/2048
18. Obeagu, E. I., Nwosu, D. C., Ugwu, O. P. C. and **Alum, E. U.** Adverse Drug Reactions in HIV/AIDS Patients on Highly Active Antiretro Viral Therapy: A Review of Prevalence. NEWPORT INTERNATIONAL JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES (NIJSES). 2023; 4(1):43-47. https://doi.org/10.59298/NIJSES/2023/10.6.1000

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

19. Alum, E. U.,Obeagu, E. I., Ugwu, O. P. C., Samson, A. O., Adepoju, A. O., Amusa, M. O. Inclusion of nutritional counseling and mental health services in HIV/AIDS management: A paradigm shift. Medicine (Baltimore). 2023;102(41):e35673. http://dx.doi.org/10.1097/MD.0000000000035673.PMID: 37832059; PMCID: PMC10578718.
20. Mekonnen H, Manyazewal T, Kajogoo VD, Getachew Assefa D, Gugsa Bekele J, Tolossa Debela D. Advances in HIV self-testing: Systematic review of current developments and the road ahead in high-burden countries of Africa. SAGE Open Med. 2023 Dec 29; 12:20503121231220788. doi: 10.1177/20503121231220788. PMID: 38162911; PMCID: PMC10757441.
21. Obeagu, E. I., Obeagu, G. U., Alum, E. U. and Ugwu, O. P. C. Anemia as a Prognostic Marker for Disease Progression in HIV Infection. *IAA Journal of Biological Sciences.* 2023; 11(1):33-44. https://doi.org/10.59298/IAAJB/2023/3.2.23310
22. Thakarar K, Nenninger K, Agmas W. Harm Reduction Services to Prevent and Treat Infectious Diseases in People Who Use Drugs. Infect Dis Clin North Am. 2020 Sep;34(3):605-620. doi: 10.1016/j.idc.2020.06.013. PMID: 32782104; PMCID: PMC7596878.
23. Obeagu, E. I., Obeagu, G. U., Alum, E. U. and Ugwu, O. P. C. Comprehensive Review of Antiretroviral Therapy Effects on Red Blood Cells in HIV Patients. *INOSR Experimental Sciences.* 2023; 12(3):63-72. https://doi.org/10.59298/INOSRES/2023/6.3.21322
24. Cobb DA, Smith NA, Edagwa BJ, McMillan JM. Long-acting approaches for delivery of antiretroviral drugs for prevention and treatment of HIV: a review of recent research. Expert Opin Drug Deliv. 2020 Sep;17(9):1227-1238. doi: 10.1080/17425247.2020.1783233. Epub 2020 Jul 6. PMID: 32552187; PMCID: PMC7442675.
25. Brizzi M, Pérez SE, Michienzi SM, Badowski ME. Long-acting injectable antiretroviral therapy: will it change the future of HIV treatment? Ther Adv Infect Dis. 2023 Jan 31; 10:20499361221149773. doi: 10.1177/20499361221149773. PMID: 36741193; PMCID: PMC9893397.
26. Griffith SA, McCoy LE. To bnAb or Not to bnAb: Defining Broadly Neutralising Antibodies Against HIV-1. Front Immunol. 2021 Oct 19;12:708227. doi: 10.3389/fimmu.2021.708227. PMID: 34737737; PMCID: PMC8560739.
27. Obeagu, E. I., Obeagu, G. U., Alum, E. U. and Ugwu, O. P. C. Persistent Immune Activation and Chronic Inflammation: Unraveling Their Impact on Anemia in HIV Infection. *INOSR Experimental Sciences.* 2023; 12(3):73-84. https://doi.org/10.59298/INOSRES/2023/7.3.21322
28. Masters MC, Krueger KM, Williams JL, Morrison L, Cohn SE. Beyond one pill, once daily: current challenges of antiretroviral therapy management in the United States. Expert Rev Clin Pharmacol. 2019 Dec;12(12):1129-1143. doi: 10.1080/17512433.2019.1698946. PMID: 31774001; PMCID: PMC7073258.
29. Ezike TC, Okpala US, Onoja UL, Nwike CP, Ezeako EC, Okpara OJ, Okoroafor CC, Eze SC, Kalu OL, Odoh EC, Nwadike UG, Ogbodo JO, Umeh BU, Ossai EC, Nwanguma BC. Advances in drug delivery systems, challenges and future directions. Heliyon. 2023 Jun 24;9(6):e17488. doi: 10.1016/j.heliyon.2023.e17488. PMID: 37416680; PMCID: PMC10320272.
30. Mu Y, Kodidela S, Wang Y, Kumar S, Cory TJ. The dawn of precision medicine in HIV: state of the art of pharmacotherapy. Expert Opin Pharmacother. 2018 Oct;19(14):1581-1595. doi: 10.1080/14656566.2018.1515916. Epub 2018 Sep 20. PMID: 30234392; PMCID: PMC6291855.
31. Kumbale CM, Voit EO. Toward Personalized Medicine for HIV/AIDS. J AIDS HIV Treat. 2021;3(2):37-41. doi: 10.33696/AIDS.3.020. PMID: 34414403; PMCID: PMC8372994
32. Obeagu, E. I., Obeagu, G. U., Alum, E. U. and Ugwu, O. P. C. Understanding the Impact of HIV-Associated Bone Marrow Alterations on Erythropoiesis. *INOSR Scientific Research.* 2023; 10(1):1-11. https://doi.org/10.59298/INOSRSR/2023/1.2.12222
33. Nicolau, V., Brandão, D., Rua, T. *et al.* Organisation and integrated healthcare approaches for people living with HIV, multimorbidity, or both: a systematic review. *BMC Public Health* **23**, 1579 (2023). https://doi.org/10.1186/s12889-023-16485-y
34. Obeagu, E. I., Obeagu, G. U., Alum, E. U. and Ugwu, O. P. C. Advancements in Immune Augmentation Strategies for HIV Patients. *IAA Journal of Biological Sciences.* 2023; 11(1):1-11. https://doi.org/10.59298/IAAJB/2023/1.2.23310
35. Berlacher M, Mercer T, Apondi EO, Mwangi W, Were E, McHenry MS. Integrating Prevention of Mother-to-Child Transmission of HIV Care into General Maternal Child Health Care in Western Kenya. Int J MCH AIDS. 2021;10(1):19-28. doi: 10.21106/ijma.429. Epub 2020 Dec 30. PMID: 33442489; PMCID: PMC7792744.
36. Cuadros DF, Huang Q, Mathenjwa T, Gareta D, Devi C, Musuka G. Unlocking the potential of telehealth in Africa for HIV: opportunities, challenges, and pathways to equitable healthcare delivery. Front Digit

OPEN ACCESS
ONLINE ISSN: 2992-5460
PRINT ISSN: 2992-6041

Health. 2024 Mar 4;6:1278223. doi: 10.3389/fdgth.2024.1278223. PMID: 38500968; PMCID: PMC10944905.

37. Burrus O, Gupta C, Ortiz A, Zulkiewicz B, Furberg R, Uhrig J, Harshbarger C, Lewis MA. Principles for Developing Innovative HIV Digital Health Interventions: The Case of Positive Health Check. Med Care. 2018 Sep;56(9):756-760. doi: 10.1097/MLR.0000000000000957. PMID: 30001252; PMCID: PMC8824315.
38. Alowais, S.A., Alghamdi, S.S., Alsuhebany, N. *et al.* Revolutionizing healthcare: the role of artificial intelligence in clinical practice. *BMC Med Educ* **23**, 689 (2023). https://doi.org/10.1186/s12909-023-04698-z
39. Mason M, Cho Y, Rayo J, Gong Y, Harris M, Jiang Y. Technologies for Medication Adherence Monitoring and Technology Assessment Criteria: Narrative Review. JMIR Mhealth Uhealth. 2022 Mar 10;10(3):e35157. doi: 10.2196/35157. PMID: 35266873; PMCID: PMC8949687.
40. Dayer L, Heldenbrand S, Anderson P, Gubbins PO, Martin BC. Smartphone medication adherence apps: potential benefits to patients and providers. J Am Pharm Assoc (2003). 2013 Mar-Apr;53(2):172-81. doi: 10.1331/JAPhA.2013.12202. PMID: 23571625; PMCID: PMC3919626.
41. Msosa, T.C., Swai, I., Sumari-de Boer, M. *et al.* The effect of a customised digital adherence tool on HIV treatment outcomes in young people living with HIV (YPLHIV) in Blantyre, Malawi: a protocol for a randomized controlled trial. *Trials* **24**, 535 (2023). https://doi.org/10.1186/s13063-023-07496-6
42. Shrivastava, R., Fonjungo, P.N., Kebede, Y. *et al.* Role of public-private partnerships in achieving UNAIDS HIV treatment targets. *BMC Health Serv Res* **19**, 46 (2019). https://doi.org/10.1186/s12913-018-3744-z
43. Emmanuel Ifeanyi Obeagu, Nwanganga Ihuoma Ubosi, Getrude Uzoma Obeagu, Hauwa Ali Buhari and Simeon Ikechukwu Egba (2023) Storms and struggles: Managing HIV Amid Natural Disasters Int. J. Curr. Res. Chem. Pharm. Sci. (2023). 10(11): 14-25
44. Joudyian, N., Doshmangir, L., Mahdavi, M. *et al.* Public-private partnerships in primary health care: a scoping review. *BMC Health Serv Res* **21**, 4 (2021). https://doi.org/10.1186/s12913-020-05979-9
45. Strasser S, Stauber C, Shrivastava R, Riley P, O'Quin K. Collective insights of public-private partnership impacts and sustainability: A qualitative analysis. PLoS One. 2021 Jul 20;16(7):e0254495. doi: 10.1371/journal.pone.0254495. PMID: 34283847; PMCID: PMC8291689.
46. Carè R, De Lisa R. Social Impact Bonds for a Sustainable Welfare State: The Role of Enabling Factors. *Sustainability*. 2019; 11(10):2884. https://doi.org/10.3390/su11102884
47. Mishra, A.K., Dash, A.K. Development impact bonds in developing countries: an emerging innovation for achieving social outcomes. *J. Soc. Econ. Dev.* **25** (Suppl 1), 22–48 (2023). https://doi.org/10.1007/s40847-022-00213-0
48. Sirisawat S, Chatjuthamard P, Kiattisin S, Treepongkaruna S. The future of digital donation crowdfunding. PLoS One. 2022 Nov 11;17(11):e0275898. doi: 10.1371/journal.pone.0275898. PMID: 36367868; PMCID: PMC9651591.

CITE AS: Mugisha Emmanuel K. (2024). Innovations in HIV Prevention and Treatment: The Future of HIV Care. NEWPORT INTERNATIONAL JOURNAL OF RESEARCH IN MEDICAL SCIENCES, 5(3):65-70
https://doi.org/10.59298/NIJRMS/2024/5.3.6570